SOCRA - Society of Clinical Research Associates Audits, Monitoring, and Inspections Questions and Answers 1 — Questions and Answers
Question 1: Which of the following best describes the primary purpose of a sponsor-initiated quality assurance audit of a clinical trial site?
- To perform source data verification for 100% of all data points entered into the CRF.
- To provide a systematic and independent examination of trial-related activities and documents to determine compliance with the protocol, GCP, and regulatory requirements. (Correct answer)
- To train the site staff on the protocol and investigational product accountability.
- To report serious adverse events directly to the regulatory authorities on behalf of the site.
Correct answer: To provide a systematic and independent examination of trial-related activities and documents to determine compliance with the protocol, GCP, and regulatory requirements.
A quality assurance audit is a formal, independent evaluation to ensure compliance and data integrity. [3, 4] It is distinct from monitoring (which may involve extensive source data verification), site training, or regulatory reporting, which are separate functions. [3]
Question 2: A clinical research site receives notification from the FDA of a forthcoming 'for-cause' inspection. This type of inspection is most likely triggered by what?
- A standard review process for a New Drug Application (NDA) submission.
- A randomly selected site as part of the FDA's routine bioresearch monitoring program.
- A specific concern, such as a complaint, unusual pattern of adverse events, or evidence of significant non-compliance. (Correct answer)
- The site enrolling the highest number of participants in a multi-center trial.
Correct answer: A specific concern, such as a complaint, unusual pattern of adverse events, or evidence of significant non-compliance.
A 'for-cause' inspection is initiated in response to specific concerns or reports that raise questions about the conduct of the study at a site. [2, 7, 10] Routine or pre-approval inspections are not classified as 'for-cause'.
Question 3: During a routine on-site monitoring visit, a Clinical Research Associate (CRA) is responsible for all of the following activities EXCEPT:
- Verifying that informed consent was obtained prior to any study-specific procedures.
- Comparing data in the source documents with the entries in the Case Report Forms (CRFs).
- Checking the storage conditions and accountability of the investigational product.
- Issuing an official FDA Form 483 for observed regulatory non-compliance. (Correct answer)
Correct answer: Issuing an official FDA Form 483 for observed regulatory non-compliance.
Issuing a Form FDA 483, which lists inspectional observations, is a function reserved for an FDA inspector at the conclusion of a regulatory inspection. [16, 20] A CRA's role is to identify and help correct issues, but they do not have the regulatory authority to issue this form.
Question 4: An FDA inspector concludes an inspection of a clinical site and issues a Form FDA 483 with three observations. What is the most critical next step for the Principal Investigator?
- Wait for the sponsor to handle all communication with the FDA.
- Submit a formal written response to the FDA, typically within 15 business days, detailing a corrective and preventive action (CAPA) plan. (Correct answer)
- Immediately stop all trial activities until the observations are resolved.
- Appeal the findings to the Institutional Review Board (IRB).
Correct answer: Submit a formal written response to the FDA, typically within 15 business days, detailing a corrective and preventive action (CAPA) plan.
Upon receiving a Form FDA 483, the investigator is expected to provide a timely written response to the FDA, generally within 15 business days. [18, 22] This response should address each observation and outline the site's plan for corrective and preventive actions. [18]
Question 5: A sponsor is implementing a risk-based monitoring approach for a large, multi-center trial. Which of the following best characterizes this strategy?
- Eliminating all on-site monitoring visits in favor of remote data review only.
- Focusing monitoring efforts on critical data and processes, with the intensity and frequency of monitoring tailored to sites identified as having higher risk. (Correct answer)
- Requiring 100% source data verification for every participant at every site, regardless of site performance.
- Assigning the responsibility of site monitoring entirely to the Institutional Review Board (IRB).
Correct answer: Focusing monitoring efforts on critical data and processes, with the intensity and frequency of monitoring tailored to sites identified as having higher risk.
Risk-based monitoring (RBM), as encouraged by ICH E6(R2), involves identifying and prioritizing risks to critical trial processes and data, then focusing monitoring activities on those areas of highest risk. [28, 19] It does not necessarily eliminate on-site visits but tailors the monitoring strategy based on risk factors. [19, 28]
Question 6: During an FDA inspection, the inspector requests access to the electronic medical records (EMR) of enrolled subjects, which are the designated source documents. The site staff should:
- Provide direct, supervised access to the relevant sections of the EMR for the subjects who provided consent. (Correct answer)
- Refuse access, stating that EMRs are confidential hospital property and not subject to FDA review.
- Print out every page of the subjects' entire medical history for the inspector to review.
- Tell the inspector to request the records directly from the hospital's legal department.
Correct answer: Provide direct, supervised access to the relevant sections of the EMR for the subjects who provided consent.
Investigators are required by regulation (e.g., 21 CFR 312.68) to permit FDA representatives to access, copy, and verify records related to the clinical investigation. [23] This includes providing supervised access to EMRs that serve as source documentation. Refusing access is a serious regulatory violation. [23]
SOCRA - Society of Clinical Research Associates Audits, Monitoring, and Inspections Questions and Answers 1
Which of the following best describes the primary purpose of a sponsor-initiated quality assurance audit of a clinical trial site?